This bibliographic study by Andrew Garratt, Louise Schmidt, Anne Mackintosh, and Ray Fitzpatrick aims to assess the growth and availability of patient-assessed health outcome measures across various specialties. The study conducted systematic searches in multiple electronic databases to identify developmental and evaluative work related to these measures. The main outcome measures included disease or population-specific, dimension-specific, generic, individualized, and utility measures. The results showed that 3921 reports met the inclusion criteria, with 46% being disease or population-specific, 22% generic, 18% dimension-specific, 10% utility, and 1% individualized measures. The number of new reports of development and evaluation increased from 144 to 650 per year between 1990 and 1999, with disease-specific measures showing exponential growth. Over 30% of evaluations were in cancer, rheumatology, musculoskeletal disorders, and older people's health. Generic measures like the SF-36, sickness impact profile, and Nottingham health profile accounted for 16% of the reports. The study concludes that while there is a significant growth in the development and evaluation of patient-assessed measures, there is a lack of standardization, particularly in disease-specific measures. Recommendations for selecting patient-assessed measures are needed to ensure their effective application.This bibliographic study by Andrew Garratt, Louise Schmidt, Anne Mackintosh, and Ray Fitzpatrick aims to assess the growth and availability of patient-assessed health outcome measures across various specialties. The study conducted systematic searches in multiple electronic databases to identify developmental and evaluative work related to these measures. The main outcome measures included disease or population-specific, dimension-specific, generic, individualized, and utility measures. The results showed that 3921 reports met the inclusion criteria, with 46% being disease or population-specific, 22% generic, 18% dimension-specific, 10% utility, and 1% individualized measures. The number of new reports of development and evaluation increased from 144 to 650 per year between 1990 and 1999, with disease-specific measures showing exponential growth. Over 30% of evaluations were in cancer, rheumatology, musculoskeletal disorders, and older people's health. Generic measures like the SF-36, sickness impact profile, and Nottingham health profile accounted for 16% of the reports. The study concludes that while there is a significant growth in the development and evaluation of patient-assessed measures, there is a lack of standardization, particularly in disease-specific measures. Recommendations for selecting patient-assessed measures are needed to ensure their effective application.